Humana (NYSE:HUM) Price Target Lowered to $185.00 at Leerink Partners

Humana (NYSE:HUM) had its price objective lowered by Leerink Partners from $267.00 to $185.00 in a note issued to investors on Thursday,MarketScreener reports. The brokerage currently has a “market perform” rating on the insurance provider’s stock. Leerink Partners’ price objective indicates a potential upside of 5.93% from the company’s previous close.

Several other research analysts have also commented on the company. Cantor Fitzgerald dropped their price target on Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a research report on Thursday. The Goldman Sachs Group lowered their price objective on Humana from $235.00 to $215.00 and set a “sell” rating for the company in a research note on Monday, November 24th. Wolfe Research boosted their target price on Humana from $300.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. Finally, KeyCorp reaffirmed a “sector weight” rating on shares of Humana in a research note on Friday, December 12th. Seven equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $263.05.

Humana Stock Down 0.4%

NYSE HUM opened at $174.65 on Thursday. The stock has a 50 day moving average price of $247.61 and a 200-day moving average price of $261.75. Humana has a one year low of $169.61 and a one year high of $315.35. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02. The company has a market capitalization of $21.01 billion, a P/E ratio of 16.34, a P/E/G ratio of 1.50 and a beta of 0.44.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 1.02% and a return on equity of 12.86%. The company had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. During the same quarter in the prior year, the firm earned ($2.16) earnings per share. Humana’s revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Humana by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock valued at $3,652,890,000 after buying an additional 106,030 shares during the period. Dodge & Cox increased its position in shares of Humana by 5.6% during the second quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock worth $2,775,562,000 after acquiring an additional 597,705 shares during the period. Capital International Investors raised its stake in shares of Humana by 113.9% during the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after acquiring an additional 3,097,571 shares in the last quarter. State Street Corp boosted its holdings in shares of Humana by 1.1% in the second quarter. State Street Corp now owns 5,377,390 shares of the insurance provider’s stock valued at $1,319,334,000 after purchasing an additional 58,094 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock worth $1,151,759,000 after purchasing an additional 1,008,514 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Stories Impacting Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Management projects ~25% Medicare Advantage membership growth in 2026 — scale gains could boost revenue and long‑term franchise value if margins recover. Humana outlines 25% Medicare Advantage membership growth for 2026
• Positive Sentiment: Revenue beat: Q4 revenue rose ~11% y/y to ~$32.6B, helped by CenterWell performance — shows underlying top‑line momentum despite profitability headwinds. Humana Incurs Q4 Loss, Revenues Up Y/Y on CenterWell Unit Strength
• Neutral Sentiment: Q4 EPS (non‑GAAP/adjusted context) slightly beat consensus but the company still reported a substantial GAAP loss; investors need to parse adjusted metrics vs. GAAP. Humana Reports Fourth Quarter 2025 Financial Results
• Negative Sentiment: FY‑2026 EPS guidance set at $9.00 vs. consensus ~$12.03 — a material cut to near‑term profitability expectations and the main driver of the stock decline. Humana forecasts 2026 profit below estimates
• Negative Sentiment: Lower quality (Star) ratings and Medicare Advantage rate pressure are expected to reduce margins and government benchmarks for plan payments — a structural headwind for 2026 results. Humana forecasts 2026 profit pressure as lower quality ratings weigh
• Negative Sentiment: Rising medical costs drove a widened Q4 GAAP loss (reported as roughly $796M in some coverage), adding to near‑term margin pressure. Humana Stock Falls on Disappointing Earnings Forecast
• Negative Sentiment: Market reaction: shares hit a 52‑week low and analysts are cautious, reflecting concern that reimbursement/rating dynamics and cost trends will keep profitability muted. Humana Hits 52-Week Low After Weak Profit Outlook

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.